Cargando…

A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma

Cutaneous melanoma is the most malignant skin cancer. Biomarkers for stratifying patients at initial diagnosis and informing clinical decisions are highly sought after. Here we classified melanoma patients into three immune subtypes by single-sample gene-set enrichment analysis. We further identifie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mei, Ying, Chen, Mei-Ju May, Liang, Han, Ma, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985195/ https://www.ncbi.nlm.nih.gov/pubmed/33753855 http://dx.doi.org/10.1038/s42003-021-01911-x

Ejemplares similares

Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
por: Schneider, Helga, et al.
Publicado: (2014)

Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody
por: Gao, Han, et al.
Publicado: (2020)

CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
por: Fietz, Simon, et al.
Publicado: (2020)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma
por: Wu, Xinqi, et al.
Publicado: (2018)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
por: Afzal, Muhammad Zubair, et al.
Publicado: (2018)

Development of an Immune-Related Gene Signature for Prognosis in Melanoma
por: Zhang, Jia-An, et al.
Publicado: (2021)

Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
por: Franken, M.G., et al.
Publicado: (2021)

Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma
por: Lai, Jinzhi, et al.
Publicado: (2022)

An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
por: Chen, Hongquan, et al.
Publicado: (2022)

Identification of Lactate-Related Gene Signature for Prediction of Progression and Immunotherapeutic Response in Skin Cutaneous Melanoma
por: Xie, Yalin, et al.
Publicado: (2022)

Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures
por: Gao, Guohong, et al.
Publicado: (2021)

Exploring immune-related signatures for predicting immunotherapeutic responsiveness, prognosis, and diagnosis of patients with colon cancer
por: Cao, Lichao, et al.
Publicado: (2022)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
por: Mangana, Joanna, et al.
Publicado: (2015)

Exploration of the Immune-Related Signatures and Immune Infiltration Analysis in Melanoma
por: Li, Ai-lan, et al.
Publicado: (2021)

Novel Immunotherapeutic Approaches for Neuroblastoma and Malignant Melanoma
por: Morandi, Fabio, et al.
Publicado: (2018)

Correction: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma
por: Lai, Jinzhi, et al.
Publicado: (2022)

The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature
por: Zhou, Sitong, et al.
Publicado: (2021)

Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature
por: Zhang, Chunyu, et al.
Publicado: (2021)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy
por: Anstadt, Emily J, et al.
Publicado: (2022)

The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma
por: Dong, Dong, et al.
Publicado: (2022)

Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
por: Subrahmanyam, Priyanka B., et al.
Publicado: (2018)

A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma
por: Almela, Ramón M., et al.
Publicado: (2019)

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
por: Ziogas, Dimitrios C., et al.
Publicado: (2023)

Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation
por: Guan, Renguo, et al.
Publicado: (2022)

Tumor Immune Microenvironment Characterization in Hepatocellular Carcinoma Identifies Four Prognostic and Immunotherapeutically Relevant Subclasses
por: Gao, Xingxing, et al.
Publicado: (2021)

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma
por: Speeckaert, Reinhart, et al.
Publicado: (2012)

Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA)
por: Cao, Rui, et al.
Publicado: (2020)

Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Liang-Hao, et al.
Publicado: (2021)

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
por: Yun, Seongseok, et al.
Publicado: (2016)

TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma
por: Xiao, Wenjing, et al.
Publicado: (2018)

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
por: Yu, Jui-Ling, et al.
Publicado: (2023)

Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Lianghao, et al.
Publicado: (2021)

Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature
por: Zhang, Simeng, et al.
Publicado: (2021)

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma
por: Doukas, J, et al.
Publicado: (2012)

Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma
por: Wang, Qi, et al.
Publicado: (2022)

The Immunotherapeutic Role of Type I and III Interferons in Melanoma and Non-Melanoma Skin Cancers
por: Weir, Sydney A., et al.
Publicado: (2023)

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients
por: Jensen, Christina, et al.
Publicado: (2018)

The role of CTLA-4 in immune regulation
por: Verhagen, Johan, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_3sbhteg8vjinlmt4k9o1o4bfl8